Neurogastrx, Inc., a Boston, MA-based private biopharmaceutical company focused on discovering and developing therapies for gastrointestinal disorders affecting the enteric nervous system, raised $45M in Series A financing.
The round was co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners. In conjunction with the financing, Jim O’Mara has been appointed CEO, and Klaus Veitinger, Venture Partner at OrbiMed Advisors, will become Chairman of the Board. David Allison of 5AM Ventures, Aaron Royston of venBio and Kevin Koch will be joining the board of directors.
Led by Jim O’Mara, President and Chief Executive Officer, Cyril De Colle, Founder and Chief Scientific Officer, Neurogastrx is a biopharmaceutical company focused on discovering and developing therapies for gastrointestinal disorders affecting the enteric nervous system.
The company intends to use the funds to fill out the management team and reach proof of concept with its lead asset, NG-101, which is intended to treat gastroparesis, a debilitating functional GI disorder.